MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition

Journal of Experimental Medicine

Volumn 209, Issue 4, 2012, Pages 679-696

  Horiuchi, Dai ^a   Kusdra, Leonard ^a   Huskey, Noelle E ^a   Chandriani, Sanjay ^b,g   Lenburg, Marc E ^d   Gonzalez Angulo, Ana Maria ^e   Creasman, Katelyn J ^a   Bazarov, Alexey V ^a,f   Smyth, James W ^b   Davis, Sarah E ^a,c   Yaswen, Paul ^f   Mills, Gordon B ^e   Esserman, Laura J ^a,c   Goga, Andrei ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^g Novartis Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; BIM PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; DINACICLIB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN BAK; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PUMA PROTEIN; PURVALANOL; APOPTOSIS REGULATORY PROTEIN; BCL 2 LIKE PROTEIN 11; BCL-2-LIKE PROTEIN 11; ERBB2 PROTEIN, HUMAN; MEMBRANE PROTEIN; MYC PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER PATIENT; CANCER REGRESSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LETHALITY; MOUSE; NONHUMAN; ONCOGENE MYC; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; RECURRENCE RISK; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CHEMISTRY; DRUG ANTAGONISM; DRUG SCREENING; GENETICS; MORTALITY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; FEMALE; HUMANS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861735363     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20111512     Document Type: Article

References (78)

1. Alles, M.C., M. Gardiner-Garden, D.J. Nott, Y. Wang, J.A. Foekens, R.L. Sutherland, E.A. Musgrove, and C.J. Ormandy. 2009. Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup. PLoS ONE. 4:e4710. http://dx.doi.org/10.1371/journal.pone.0004710
2. Barker, A.D., C.C. Sigman, G.J. Kelloff, N.M. Hylton, D.A. Berry, and L.J. Esserman. 2009. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Ther. 86:97-100. http://dx.doi.org/10.1038/clpt.2009.68
3. Bauer, K.R., M. Brown, R.D. Cress, C.A. Parise, and V. Caggiano. 2007. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 109:1721-1728. http://dx.doi.org/10.1002/cncr.22618
4. Ben-Porath, I., M.W. Thomson, V.J. Carey, R. Ge, G.W. Bell, A. Regev, and R.A. Weinberg. 2008. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40:499-507. http://dx.doi.org/10.1038/ng.127
5. Bertucci, F., P. Finetti, N. Cervera, B. Esterni, F. Hermitte, P. Viens, and D. Birnbaum. 2008. How basal are triple-negative breast cancers? Int. J. Cancer. 123:236-240. http://dx.doi.org/10.1002/ijc.23518
6. Bland, K.I., M.M. Konstadoulakis, M.P. Vezeridis, and H.J. Wanebo. 1995. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann. Surg. 221:706-718. http://dx.doi.org/10.1097/00000658-199506000-00010
7. Blethrow, J.D., J.S. Glavy, D.O. Morgan, and K.M. Shokat. 2008. Covalent capture of kinase-specific phosphopeptides reveals Cdk1-cyclin B substrates. Proc. Natl. Acad. Sci. USA. 105:1442-1447. http://dx.doi.org/10.1073/pnas.0708966105
8. Carey, L.A., C.M. Perou, C.A. Livasy, L.G. Dressler, D. Cowan, K. Conway, G. Karaca, M.A. Troester, C.K. Tse, S. Edmiston, et al. 2006. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 295:2492-2502. http://dx.doi.org/10.1001/jama.295.21.2492
9. Carey, L.A., E.C. Dees, L. Sawyer, L. Gatti, D.T. Moore, F. Collichio, D.W. Ollila, C.I. Sartor, M.L. Graham, and C.M. Perou. 2007. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 13:2329-2334. http://dx.doi.org/10.1158/1078-0432.CCR-06-1109
10. Chandriani, S., E. Frengen, V.H. Cowling, S.A. Pendergrass, C.M. Perou, M.L. Whitfield, and M.D. Cole. 2009. A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response. PLoS ONE. 4:e6693. http://dx.doi.org/10.1371/journal.pone.0006693
11. Chang, D.W., G.F. Claassen, S.R. Hann, and M.D. Cole. 2000. The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals. Mol. Cell. Biol. 20:4309-4319. http://dx.doi.org/10.1128/MCB.20.12.4309-4319.2000
12. Cheang, M.C., S.K. Chia, D. Voduc, D. Gao, S. Leung, J. Snider, M. Watson, S. Davies, P.S. Bernard, J.S. Parker, et al. 2009. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl. Cancer Inst. 101:736-750. http://dx.doi.org/10.1093/jnci/djp082
13. Chonghaile, T.N., and A. Letai. 2008. Mimicking the BH3 domain to kill cancer cells. Oncogene. 27:S149-S157. http://dx.doi.org/10.1038/onc.2009.52
14. Cowling, V.H., and M.D. Cole. 2006. Mechanism of transcriptional activation by the Myc oncoproteins. Semin. Cancer Biol. 16:242-252. http://dx.doi.org/10.1016/j.semcancer.2006.08.001
15. Dang, C.V. 1999. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Biol. 19:1-11.
16. Dent, R., M. Trudeau, K.I. Pritchard, W.M. Hanna, H.K. Kahn, C.A. Sawka, L.A. Lickley, E. Rawlinson, P. Sun, and S.A. Narod. 2007. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13:4429-4434. http://dx.doi.org/10.1158/1078-0432.CCR-06-3045
17. Dickson, M.A., and G.K. Schwartz. 2009. Development of cell-cycle inhibitors for cancer therapy. Curr. Oncol. 16:36-43.
18. Dohadwala, M., E.F. da Cruz e Silva, F.L. Hall, R.T. Williams, D.A. Carbonaro-Hall, A.C. Nairn, P. Greengard, and N. Berndt. 1994. Phosphorylation and inactivation of protein phosphatase 1 by cyclin-dependent kinases. Proc. Natl. Acad. Sci. USA. 91:6408-6412. http://dx.doi.org/10.1073/pnas.91.14.6408
19. Egle, A., A.W. Harris, P. Bouillet, and S. Cory. 2004. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc. Natl. Acad. Sci. USA. 101:6164-6169. http://dx.doi.org/10.1073/pnas.0401471101
20. Eilers, M., and R.N. Eisenman. 2008. Myc's broad reach. Genes Dev. 22:2755-2766. http://dx.doi.org/10.1101/gad.1712408
21. Esserman, L.J., D.A. Berry, A. DeMichele, L.A. Carey, S.E. Davis, M. Buxton, C. Hudis, J.W. Gray, C. Perou, C. Yau, et al. 2012. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). J. Clin. Oncol. In press.
22. Fong, P.C., D.S. Boss, T.A. Yap, A. Tutt, P. Wu, M. Mergui-Roelvink, P. Mortimer, H. Swaisland, A. Lau, M.J. O'Connor, et al. 2009. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361:123-134. http://dx.doi.org/10.1056/NEJMoa0900212
23. Fournier, M.V., K.J. Martin, P.A. Kenny, K. Xhaja, I. Bosch, P. Yaswen, and M.J. Bissell. 2006. Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer. Cancer Res. 66:7095-7102. http://dx.doi.org/10.1158/0008-5472.CAN-06-0515
24. Gatza, M.L., J.E. Lucas, W.T. Barry, J.W. Kim, Q. Wang, M.D. Crawford, M.B. Datto, M. Kelley, B. Mathey-Prevot, A. Potti, and J.R. Nevins. 2010. A pathway-based classification of human breast cancer. Proc. Natl. Acad. Sci. USA. 107:6994-6999. http://dx.doi.org/10.1073/pnas.0912708107
25. Goga, A., D. Yang, A.D. Tward, D.O. Morgan, and J.M. Bishop. 2007. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat. Med. 13:820-827. http://dx.doi.org/10.1038/nm1606
26. Gonzalez-Angulo, A.M., K. Stemke-Hale, S.L. Palla, M. Carey, R. Agarwal, F. Meric-Berstam, T.A. Traina, C. Hudis, G.N. Hortobagyi, W.L. Gerald, et al. 2009. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin. Cancer Res. 15:2472-2478. http://dx.doi.org/10.1158/1078-0432.CCR-08-1763
27. Grandori, C., S.M. Cowley, L.P. James, and R.N. Eisenman. 2000. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu. Rev. Cell Dev. Biol. 16:653-699. http://dx.doi.org/10.1146/annurev.cellbio.16.1.653
28. Gray, N.S., L. Wodicka, A.M. Thunnissen, T.C. Norman, S. Kwon, F.H. Espinoza, D.O. Morgan, G. Barnes, S. LeClerc, L. Meijer, et al. 1998. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 281:533-538. http://dx.doi.org/10.1126/science.281.5376.533
29. Guan, Y., W.L. Kuo, J.L. Stilwell, H. Takano, A.V. Lapuk, J. Fridlyand, J.H. Mao, M. Yu, M.A. Miller, J.L. Santos, et al. 2007. Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin. Cancer Res. 13:5745-5755. http://dx.doi.org/10.1158/1078-0432.CCR-06-2882
30. Gurel, B., T. Iwata, C.M. Koh, R.B. Jenkins, F. Lan, C. Van Dang, J.L. Hicks, J. Morgan, T.C. Cornish, S. Sutcliffe, et al. 2008. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod. Pathol. 21:1156-1167. http://dx.doi.org/10.1038/modpathol.2008.111
31. Hemann, M.T., A. Bric, J. Teruya-Feldstein, A. Herbst, J.A. Nilsson, C. Cordon-Cardo, J.L. Cleveland, W.P. Tansey, and S.W. Lowe. 2005. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature. 436:807-811. http://dx.doi.org/10.1038/nature03845
32. Hennessy, B.T., Y. Lu, E. Poradosu, Q. Yu, S. Yu, H. Hall, M.S. Carey, M. Ravoori, A.M. Gonzalez-Angulo, R. Birch, et al. 2007. Pharmacodynamic markers of perifosine efficacy. Clin. Cancer Res. 13:7421-7431. http://dx.doi.org/10.1158/1078-0432.CCR-07-0760
33. Hu, J., X. He, K.A. Baggerly, K.R. Coombes, B.T. Hennessy, and G.B. Mills. 2007. Non-parametric quantification of protein lysate arrays. Bioinformatics. 23:1986-1994. http://dx.doi.org/10.1093/bioinformatics/btm283
34. Huang, M.J., Y.C. Cheng, C.R. Liu, S. Lin, and H.E. Liu. 2006. A smallmolecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp. Hematol. 34:1480-1489. http://dx.doi.org/10.1016/j.exphem.2006.06.019
35. Hübner, A., T. Barrett, R.A. Flavell, and R.J. Davis. 2008. Multisite phosphorylation regulates Bim stability and apoptotic activity. Mol. Cell. 30:415-425. http://dx.doi.org/10.1016/j.molcel.2008.03.025
36. Irvin, W.J. Jr., and L.A. Carey. 2008. What is triple-negative breast cancer? Eur. J. Cancer. 44:2799-2805. http://dx.doi.org/10.1016/j.ejca.2008.09.034
37. Jain, A.N., K. Chin, A.L. Børresen-Dale, B.K. Erikstein, P. Eynstein Lonning, R. Kaaresen, and J.W. Gray. 2001. Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival. Proc. Natl. Acad. Sci. USA. 98: 7952-7957. http://dx.doi.org/10.1073/pnas.151241198
38. Jones, D. 2010. Adaptive trials receive boost. Nat. Rev. Drug Discov. 9:345-348. http://dx.doi.org/10.1038/nrd3174
39. Lee, G.Y., P.A. Kenny, E.H. Lee, and M.J. Bissell. 2007. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat. Methods. 4:359-365. http://dx.doi.org/10.1038/nmeth1015
40. Liang, J., S.H. Shao, Z.X. Xu, B. Hennessy, Z. Ding, M. Larrea, S. Kondo, D.J. Dumont, J.U. Gutterman, C.L. Walker, et al. 2007. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat. Cell Biol. 9: 218-224. http://dx.doi.org/10.1038/ncb1537
41. Liedtke, C., C. Mazouni, K.R. Hess, F. André, A. Tordai, J.A. Mejia, W.F. Symmans, A.M. Gonzalez-Angulo, B. Hennessy, M. Green, et al. 2008. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 26:1275-1281. http://dx.doi.org/10.1200/JCO.2007.14.4147
42. Livak, K.J., and T.D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402-408. http://dx.doi.org/10.1006/meth.2001.1262
43. Livasy, C.A., G. Karaca, R. Nanda, M.S. Tretiakova, O.I. Olopade, D.T. Moore, and C.M. Perou. 2006. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod. Pathol. 19:264-271. http://dx.doi.org/10.1038/modpathol.3800528
44. Lowe, S.W., E. Cepero, and G. Evan. 2004. Intrinsic tumour suppression. Nature. 432:307-315. http://dx.doi.org/10.1038/nature03098
45. Malumbres, M., P. Pevarello, M. Barbacid, and J.R. Bischoff. 2008. CDK inhibitors in cancer therapy: what is next? Trends Pharmacol. Sci. 29:16-21. http://dx.doi.org/10.1016/j.tips.2007.10.012
46. Martin, K.J., D.R. Patrick, M.J. Bissell, and M.V. Fournier. 2008. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS ONE. 3:e2994. http://dx.doi.org/10.1371/journal.pone.0002994
47. Masutomi, K., R. Possemato, J.M. Wong, J.L. Currier, Z. Tothova, J.B. Manola, S. Ganesan, P.M. Lansdorp, K. Collins, and W.C. Hahn. 2005. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc. Natl. Acad. Sci. USA. 102:8222-8227. http://dx.doi.org/10.1073/pnas.0503095102
48. Meyer, N., and L.Z. Penn. 2008. Reflecting on 25 years with MYC. Nat. Rev. Cancer. 8:976-990. http://dx.doi.org/10.1038/nrc2231
49. Molenaar, J.J., M.E. Ebus, D. Geerts, J. Koster, F. Lamers, L.J. Valentijn, E.M. Westerhout, R. Versteeg, and H.N. Caron. 2009. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc. Natl. Acad. Sci. USA. 106:12968-12973. http://dx.doi.org/10.1073/pnas.0901418106
50. Naidu, R., N.A. Wahab, M. Yadav, and M.K. Kutty. 2002. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction. Int. J. Mol. Med. 9:189-196.
51. Neve, R.M., K. Chin, J. Fridlyand, J. Yeh, F.L. Baehner, T. Fevr, L. Clark, N. Bayani, J.P. Coppe, F. Tong, et al. 2006. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 10:515-527. http://dx.doi.org/10.1016/j.ccr.2006.10.008
52. Nguyen, M., R.C. Marcellus, A. Roulston, M. Watson, L. Serfass, S.R. Murthy Madiraju, D. Goulet, J. Viallet, L. Bélec, X. Billot, et al. 2007. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl. Acad. Sci. USA. 104:19512-19517. http://dx.doi.org/10.1073/pnas.0709443104
53. Nijjar, T., E. Bassett, J. Garbe, Y. Takenaka, M.R. Stampfer, D. Gilley, and P. Yaswen. 2005. Accumulation and altered localization of telomere-associated protein TRF2 in immortally transformed and tumor-derived human breast cells. Oncogene. 24:3369-3376. http://dx.doi.org/10.1038/sj.onc.1208482
54. O'Connor, L., A. Strasser, L.A. O'Reilly, G. Hausmann, J.M. Adams, S. Cory, and D.C. Huang. 1998. Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J. 17:384-395. http://dx.doi.org/10.1093/emboj/17.2.384
55. Oltersdorf, T., S.W. Elmore, A.R. Shoemaker, R.C. Armstrong, D.J. Augeri, B.A. Belli, M. Bruncko, T.L. Deckwerth, J. Dinges, P.J. Hajduk, et al. 2005. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 435:677-681. http://dx.doi.org/10.1038/nature03579
56. Parry, D., T. Guzi, F. Shanahan, N. Davis, D. Prabhavalkar, D. Wiswell, W. Seghezzi, K. Paruch, M.P. Dwyer, R. Doll, et al. 2010. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol. Cancer Ther. 9:2344-2353. http://dx.doi.org/10.1158/1535-7163.MCT-10-0324
57. Perou, C.M., T. Sørlie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, C.A. Rees, J.R. Pollack, D.T. Ross, H. Johnsen, L.A. Akslen, et al. 2000. Molecular portraits of human breast tumours. Nature. 406:747-752. http://dx.doi.org/10.1038/35021093
58. Reinhardt, H.C., H. Jiang, M.T. Hemann, and M.B. Yaffe. 2009. Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle. 8: 3112-3119. http://dx.doi.org/10.4161/cc.8.19.9626
59. Ruzinova, M.B., T. Caron, and S.J. Rodig. 2010. Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation. Am. J. Surg. Pathol. 34:882-891. http://dx.doi.org/10.1097/PAS.0b013e3181db83af
60. Sarrió, D., S.M. Rodriguez-Pinilla, D. Hardisson, A. Cano, G. Moreno-Bueno, and J. Palacios. 2008. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 68:989-997. http://dx.doi.org/10.1158/0008-5472.CAN-07-2017
61. Schmelzle, T., A.A. Mailleux, M. Overholtzer, J.S. Carroll, N.L. Solimini, E.S. Lightcap, O.P. Veiby, and J.S. Brugge. 2007. Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis. Proc. Natl. Acad. Sci. USA. 104: 3787-3792. http://dx.doi.org/10.1073/pnas.0700115104
62. Schneider, B.P., E.P. Winer, W.D. Foulkes, J. Garber, C.M. Perou, A. Richardson, G.W. Sledge, and L.A. Carey. 2008. Triple-negative breast cancer: risk factors to potential targets. Clin. Cancer Res. 14:8010-8018. http://dx.doi.org/10.1158/1078-0432.CCR-08-1208
63. Sears, R., F. Nuckolls, E. Haura, Y. Taya, K. Tamai, and J.R. Nevins. 2000. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 14:2501-2514. http://dx.doi.org/10.1101/gad.836800
64. Seo, H.R., J. Kim, S. Bae, J.W. Soh, and Y.S. Lee. 2008. Cdk5-mediated phosphorylation of c-Myc on Ser-62 is essential in transcriptional activation of cyclin B1 by cyclin G1. J. Biol. Chem. 283:15601-15610. http://dx.doi.org/10.1074/jbc.M800987200
65. Shapiro, G.I. 2006. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24:1770-1783. http://dx.doi.org/10.1200/JCO.2005.03.7689
66. Sierra, A., X. Castellsague, A. Escobedo, A. Moreno, T. Drudis, and A. Fabra. 1999. Synergistic cooperation between c-Myc and Bcl-2 in lymph node progression of T1 human breast carcinomas. Breast Cancer Res. Treat. 54:39-45. http://dx.doi.org/10.1023/A:1006120006471
67. Sørlie, T., C.M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, et al. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA. 98:10869-10874. http://dx.doi.org/10.1073/pnas.191367098
68. Soucek, L., J. Whitfield, C.P. Martins, A.J. Finch, D.J. Murphy, N.M. Sodir, A.N. Karnezis, L.B. Swigart, S. Nasi, and G.I. Evan. 2008. Modelling Myc inhibition as a cancer therapy. Nature. 455:679-683. http://dx.doi.org/10.1038/nature07260
69. Stemke-Hale, K., A.M. Gonzalez-Angulo, A. Lluch, R.M. Neve, W.L. Kuo, M. Davies, M. Carey, Z. Hu, Y. Guan, A. Sahin, et al. 2008. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 68:6084-6091. http://dx.doi.org/10.1158/0008-5472.CAN-07-6854
70. Symmans, W.F., F. Peintinger, C. Hatzis, R. Rajan, H. Kuerer, V. Valero, L. Assad, A. Poniecka, B. Hennessy, M. Green, et al. 2007. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J. Clin. Oncol. 25:4414-4422. http://dx.doi.org/10.1200/JCO.2007.10.6823
71. Tibes, R., Y. Qiu, Y. Lu, B. Hennessy, M. Andreeff, G.B. Mills, and S.M. Kornblau. 2006. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol. Cancer Ther. 5:2512-2521. http://dx.doi.org/10.1158/1535-7163.MCT-06-0334
72. Tutt, A., M. Robson, J.E. Garber, S.M. Domchek, M.W. Audeh, J.N. Weitzel, M. Friedlander, B. Arun, N. Loman, R.K. Schmutzler, et al. 2010. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 376:235-244. http://dx.doi.org/10.1016/S0140-6736(10)60892-6
73. van 't Veer, L.J., H. Dai, M.J. van de Vijver, Y.D. He, A.A. Hart, M. Mao, H.L. Peterse, K. van der Kooy, M.J. Marton, A.T. Witteveen, et al. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:530-536. http://dx.doi.org/10.1038/415530a
74. Voduc, K.D., M.C. Cheang, S. Tyldesley, K. Gelmon, T.O. Nielsen, and H. Kennecke. 2010. Breast cancer subtypes and the risk of local and regional relapse. J. Clin. Oncol. 28:1684-1691. http://dx.doi.org/10.1200/JCO.2009.24.9284
75. Wang, Y., I.H. Engels, D.A. Knee, M. Nasoff, Q.L. Deveraux, and K.C. Quon. 2004. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell. 5:501-512. http://dx.doi.org/10.1016/S1535-6108(04)00113-8
76. Weaver, V.M., S. Lelièvre, J.N. Lakins, M.A. Chrenek, J.C. Jones, F. Giancotti, Z. Werb, and M.J. Bissell. 2002. beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell. 2:205-216. http://dx.doi.org/10.1016/S1535-6108(02)00125-3
77. Wong, D.J., H. Liu, T.W. Ridky, D. Cassarino, E. Segal, and H.Y. Chang. 2008. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell. 2:333-344. http://dx.doi.org/10.1016/j.stem.2008.02.009
78. Yang, D., H. Liu, A. Goga, S. Kim, M. Yuneva, and J.M. Bishop. 2010. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc. Natl. Acad. Sci. USA. 107:13836-13841. http://dx.doi.org/10.1073/pnas.1008366107